Morgan Stanley
EWTX icon

Morgan Stanley’s Edgewise Therapeutics EWTX Stock Holding History

Morgan Stanley’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2M Sell
1,948,597
-297,431
-13% -$10.3M ﹤0.01% 1773
2026
Q1 		$70.7M Sell
2,246,028
-664,853
-23% -$19.2M ﹤0.01% 1760
2025
Q4 		$72.2M Buy
2,910,881
+2,041,203
+235% +$41M ﹤0.01% 1738
2025
Q3 		$14.1M Buy
869,678
+141,964
+20% +$2.01M ﹤0.01% 3232
2025
Q2 		$9.54M Buy
727,714
+318,717
+78% +$4.6M ﹤0.01% 3489
2025
Q1 		$9M Sell
408,997
-27,433
-6% -$720K ﹤0.01% 3438
2024
Q4 		$11.7M Buy
436,430
+18,299
+4% +$583K ﹤0.01% 3283
2024
Q3 		$11.2M Buy
418,131
+168,157
+67% +$3.35M ﹤0.01% 3344
2024
Q2 		$4.5M Sell
249,974
-124,744
-33% -$2.18M ﹤0.01% 3976
2024
Q1 		$6.83M Sell
374,718
-75,640
-17% -$1.2M ﹤0.01% 3656
2023
Q4 		$4.93M Buy
450,358
+377,287
+516% +$2.65M ﹤0.01% 4383
2023
Q3 		$419K Sell
73,071
-27,322
-27% -$186K ﹤0.01% 5245
2023
Q2 		$778K Buy
100,393
+36,120
+56% +$305K ﹤0.01% 4980
2023
Q1 		$429K Buy
64,273
+3,972
+7% +$36.8K ﹤0.01% 5343
2022
Q4 		$539K Sell
60,301
-44,436
-42% -$417K ﹤0.01% 5207
2022
Q3 		$1.03M Buy
104,737
+57,773
+123% +$584K ﹤0.01% 4853
2022
Q2 		$374K Buy
46,964
+24,989
+114% +$189K ﹤0.01% 5565
2022
Q1 		$214K Buy
21,975
+4,798
+28% +$61.8K ﹤0.01% 5884
2021
Q4 		$262K Buy
17,177
+16,311
+1,883% +$293K ﹤0.01% 5916
2021
Q3 		$14K Buy
866
+404
+87% +$7.31K ﹤0.01% 7219
2021
Q2 		$10K Buy
+462
New +$12.6K ﹤0.01% 7227

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's EWTX Position: Q2 2026 in Review

Morgan Stanley reduced its Edgewise Therapeutics (EWTX) stake by 13% in Q2 2026, selling an estimated $10.3M and leaving 1,948,597 shares worth $79.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

Morgan Stanley first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Morgan Stanley held 1,948,597 shares of Edgewise Therapeutics worth $79.2M as of Q2 2026.
  • Morgan Stanley sold 297,431 Edgewise Therapeutics shares in Q2 2026, an estimated $10.3M.
  • Edgewise Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1773 holding.
  • Morgan Stanley first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.